Sotera Health Q2 revenue rises 6.4%, beats estimates on favorable pricing

Sotera Health

08/08/2025 12:38

Overview

Sotera Health Q2 2025 net revenues up 6.4% to $294 mln, beating estimates

Adjusted EPS rises to $0.20, exceeding analyst expectations, per LSEG data

Adjusted EBITDA grows 9.8% to $151 mln, surpassing estimates, per LSEG data

Outlook

Sotera Health raises full-year 2025 net revenue growth to 4.5%-6.0%

Company expects full-year Adjusted EBITDA growth of 6.0%-7.5%

Sotera Health sees Adjusted EPS range at $0.75-$0.82

Capital expenditures forecast lowered to $170 mln-$180 mln

Result Drivers

STERIGENICS VOLUME - Strong volume performance at Sterigenics contributed to revenue growth

NELSON LABS MARGIN - Margin expansion driven by improvements at Nelson Labs

FAVORABLE PRICING - Revenue growth supported by favorable pricing across segments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$294.34 mln
$275.90 mln (6 Analysts)
Q2 Adjusted EPS
Beat
$0.2
$0.17 (7 Analysts)
Q2 Net Income
$7.96 mln
Q2 Adjusted EBITDA
Beat
$151 mln
$137.20 mln (6 Analysts)
Q2 Pretax Profit
Miss
$18.90 mln
$74.20 mln (5 Analysts)
Q2 Gross Profit
$166.62 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Sotera Health Co is $15.50, about 27.6% above its August 7 closing price of $11.22

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNX2pZ1HW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)